GLP-1 and Muscle Loss: What to Know and What to Ask
In this guide
This article is for information only and is not medical advice. Talk to your prescriber or a qualified professional.
GLP-1 muscle loss is real in the sense that when people lose weight on these medicines, some of the lost weight is lean mass, which includes muscle but also water and organ tissue. In one large semaglutide trial, a 2025 joint advisory reports that about 38% of the weight lost was lean mass. The same advisory says structured strength training is well established to help preserve lean mass during weight reduction. What this means for your own body and function is less clear, so this page lays out what we can verify and what to ask your care team.
About Dosinha: a shot log, reminders, injection-site rotation, weight and water are free forever. See what is free and what Pro adds.
This article sits inside our GLP-1 diet guide.
What “lean mass” means
Body scans such as DXA split weight into fat mass and lean mass. Lean mass is not the same as muscle. The joint advisory describes lean body mass as including muscle and other nonfat tissues. That is why you will see different numbers quoted online: a figure for lean mass is bigger than a figure for muscle alone, and any muscle figure depends on the method used. The authors of the tirzepatide study below also note that a four-compartment model may be more accurate than DXA alone.
What the trials show
These numbers come from trial participants, mostly in small body composition subgroups, and do not predict what will happen to you.
| Study | What it measured | What it found |
|---|---|---|
| STEP 1 (semaglutide), as reported by the joint advisory | Average weight reduction of 13.6 kg | 8.3 kg (62%) was fat mass and 5.3 kg (38%) was lean body mass |
| STEP 1 DXA substudy, 95 people on semaglutide | Change from baseline at week 68 | Total fat mass down 19.3%, lean body mass down 9.7% |
| SURMOUNT-1 DXA substudy, 124 people on tirzepatide and 36 on placebo | Change at week 72 | Fat mass down 33.9% and lean mass down 10.9% on tirzepatide, versus fat down 8.2% and lean down 2.6% on placebo |
In SURMOUNT-1, the authors report that roughly 75% of the weight lost was fat and 25% was lean mass for both tirzepatide and placebo, and the split was consistent across age, sex and weight-reduction subgroups. In other words, lean mass fell along with weight, including in the placebo group. The joint advisory estimates about 20% of total weight reduction as muscle loss, and says the amount varies by sex, from 10% to 15% in females and 20% to 25% in males, in the absence of structured strength training.
What we do not know
- Function. The SURMOUNT-1 authors say their subgroup analyses were limited in size and did not evaluate physical activity or nutrient intake, and they suggest future research with direct functional outcomes such as a sit-to-stand test. The advisory says research on how GLP-1 therapy affects muscle quality and physical function is ongoing.
- Whether the loss matters for you. We did not find a source in our review that sets a threshold at which lean mass loss becomes harmful, so we will not suggest one.
- Muscle gain. We found no source showing that people on these medicines gain muscle, and we do not make that claim.
What the advisory says may help
The joint advisory says these medicines should be prescribed together with a structured exercise program, aiming for strength training at least three times a week plus at least 150 minutes of moderate aerobic exercise a week. It adds that:
- Structured strength or combined strength and aerobic training is well established to help preserve lean mass during weight reduction.
- Aerobic activity alone has a smaller effect on preserving lean mass during rapid weight reduction.
- In one randomized trial, one year of GLP-1 therapy combined with exercise training preserved bone mineral density, while GLP-1 therapy alone decreased it.
These are the advisory’s stated aims for a general population. A prescriber or a qualified trainer can adapt them to your age, joints and health. If you have never done strength training, ask about starting safely.
Protein
The advisory treats sufficient protein as a priority alongside strength training. It describes ranges that experts discuss and admits it is unclear which body weight to base them on, so the number should come from your care team. We explain the ranges in protein on a GLP-1. For practical ways to eat protein with a small appetite, see GLP-1 foods, GLP-1 snacks and GLP-1 meals and recipes.
Eating enough overall
Because very low intake raises the risk of nutrient gaps, the advisory also stresses regular small meals and a dietitian’s help. Our GLP-1 diet plan shows a weekly structure.
How clinicians may check
The advisory describes bioelectrical impedance analysis as a practical, easy way to estimate body composition and DXA as a gold standard. It also says simple functional tests, such as sit-to-stand, stair climb and timed up-and-go, can be helpful. It adds that until better measures are available, an exercise physiologist or strength trainer may be worth consulting. Ask your prescriber what, if anything, makes sense for you.
Questions to bring to your appointment
- Do you recommend a strength training program for me, and how should I start?
- Which body weight should protein goals be based on in my case?
- Should I have my nutrient levels checked?
- Is a dietitian or exercise professional available through my plan?
- What changes should make me call you?
When to call a clinician
Tell your prescriber about muscle weakness, falls, or trouble with stairs or getting up from a chair. The advisory lists muscle weakness, fatigue beyond what you would expect, excessive hair loss, poor wound healing and unusual bruising as possible signs of nutrient deficiency worth discussing. According to the Wegovy prescribing information, tell your provider right away if nausea, vomiting or diarrhea does not go away, and seek help for severe abdominal pain that may spread to the back. Your prescriber and pharmacist set your plan.
Frequently asked questions
Do GLP-1 medicines cause muscle loss?
Weight loss of any kind, including on these medicines, involves some loss of lean mass. Trial data show lean mass falling alongside fat mass, and placebo groups also lost some lean mass when they lost weight. Whether that has a functional effect for you is not settled.
Can you build muscle while on a GLP-1?
We did not find a source showing muscle gain on these medicines. The advisory says structured strength training helps preserve lean mass during weight reduction. Ask your care team what goal is realistic for you.
How do I protect muscle on a GLP-1?
The advisory points to regular strength training, enough protein and enough overall food, with a dietitian involved if possible. It does not promise any specific result.
Is lean mass loss the same as muscle loss?
No. The advisory describes lean body mass as including muscle and other nonfat tissues. It estimates about 20% of weight reduction as muscle, a lower figure than the roughly 38% that is lean body mass in STEP 1.
Keep a record you can share
Dosinha lets you log protein, water and your shot, and note how you feel, so you can notice patterns and share a record with your prescriber or dietitian. It cannot measure muscle, and it is not a substitute for a scan or an exam. See the free tools.
Sources
- Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. 2025. Muscle and bone section, exercise, monitoring, nutrient deficiency signs.
- Wilding JPH et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. Journal of the Endocrine Society, 2021. DXA substudy results.
- Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes, Obesity and Metabolism, 2025.
- FDA. Wegovy prescribing information. Revised 1/2026. Warnings and patient information.
This article is for information only and is not medical advice. Talk to your prescriber or a qualified professional.